Log in to your Inderes Free account to see all free content on this page.
Create account

Oriola

0.89 EUR

+0.79 %

7,747 following
Corporate customer

ORIOLA

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+0.79 %
-7.10 %
-24.58 %
-22.61 %
-23.14 %
-17.59 %
-37.41 %
-52.00 %
-51.61 %

Oriola is a pharmaceutical group with a particular focus on the distribution of pharmaceuticals to other players in the industry. The company offers services to pharmacies and other pharmaceutical companies, which includes, for example, negotiations with suppliers and distribution of products. The largest operations are in the Nordic and Baltic regions. The headquarters are located in Espoo.

Read more
Market cap
164.94M EUR
Turnover
164.93K EUR
P/E (adj.) (26e)
EV/EBIT (adj.) (26e)
P/B (26e)
EV/S (26e)
Dividend yield-% (26e)
Coverage
Recommendation
Accumulate
Target price
Updated
30.04.2026
Disclaimer
Rauli Juva
Rauli Juva

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
17.7.
2026

Interim report Q2'26

29.10.
2026

Interim report Q3'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Third party research

Oriola: Solid mid-term potential - Evli

With the financial targets announced earlier along with major investments known, Oriola’s CMD was limited in terms of significant new news, which we see as a positive given earlier concerns. More clarity was however provided on the roadmap to achieving...

Oriola

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Third party research

Oriola: Soft start but expecting improvement - Evli

Oriola started of the year with a lower-than-expected improvement in adj. EBITDA due to performance of the advisory business and elevated group costs, but we expect performance to pick up during the year.

Oriola
Third party research

Oriola: Softer profitability, good growth - Evli

Oriola posted fairly decent figures in Q1. Net sales and invoicing growth continued at a good pace, with the latter up 8.1% y/y. The adj. EBITDA of EUR 7.7m fell well short of our EUR 8.5m expectations, with profitability in the Services-segment declining...

Oriola
Third party research

Oriola: Expecting steady progress - Evli

Oriola reports its Q1 results on April 29th. We expect continued improvement in adj. EBITDA. We have lowered our coming year profitability estimates and adjust our target price to EUR 1.0 (1.15), ACCUMULATE-rating intact.

Oriola
Forum discussions
There have been changes in the ownership of the Swedish pharmacy company half-owned by Oriola. The Lithuanian owner of the other half has sold its stake in the Swedish pharmacy company from the Euroapotheca Group, which operated pharmacy activities, to another group company. Euroapotheca...
5/9/2026, 8:19 AM
by Aktivisti26
9
Inderes Oriola Oyj:n osavuosikatsaus tammi-maaliskuulta 2026 - Inderes Oriola Oyj:n pörssitiedote 29.4.2026 klo 8.30Oriola Oyj:n osavuosikatsaus tammi-maaliskuulta 2026Ensimmäisen vuosineljänneksen tulos odotusten mukainenTammi-maaliskuun 2026 pääkohdat Laskutus... The loss includes...
4/29/2026, 7:16 AM
by Trivial
5
Here are Rauli’s pre-event comments regarding Oriola’s CMD festivities to be held on May 12th Oriola already announced its new financial targets in connection with the Q1 results, which will be further presented at the Capital Markets Day on May 12th. We would particularly seek clarity...
5/11/2026, 5:11 AM
by Sijoittaja-alokas
4
Here are Evli’s thoughts on Oriola. Oriola started of the year with a lower-than-expected improvement in adj. EBITDA due to performance of the advisory business and elevated group costs, but we expect performance to pick up during the year. ACCUMULATE with a target price of EUR 1...
5/3/2026, 2:12 PM
by Sijoittaja-alokas
4
Here are Rauli’s quick comments on Oriola’s Q1 result. Oriola’s adj. EBITDA improved from the comparison period but fell short of our expectations. The result of the associate company Kronans continued to be loss-making and was also weaker than our expectations. As expected, the ...
4/29/2026, 8:07 AM
by Sijoittaja-alokas
4
Rauli has written a new company report on Oriola following the Q1 results Oriola’s Q1 result improved from the comparison period but fell short of our estimates. The company reiterated its positive full-year guidance, but our estimate decreased especially regarding the joint venture...
4/30/2026, 5:14 AM
by Sijoittaja-alokas
3
Rauli interviewed Oriola’s CEO Katarina Gabrielson after the Q1 release Inderes Oriola Q1'26: Uudet taloudelliset tavoitteet (eng.) - Inderes Aika: 29.04.2026 klo 13.21 Vakaan vuoden aloituksen lisäksi Oriola kertoi tulospäivänä uudesta raportointirakenteesta ja uusista taloudellisista...
4/29/2026, 12:52 PM
by Sijoittaja-alokas
3
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.